| Safety and effectiveness of appropriately and inappropriately dosed rivaroxaban or apixaban versus warfarin in patients with atrial fibrillation: a cohort study with nested case–control analyses from UK primary care | BMJ Open | 2022 |
| The Safety and Efficacy of Apixaban (Eliquis) in 5017 Post-bariatric Patients with 95.3% Follow-up: a Multicenter Study. | Obesity Surgery | 2022 |
| Thromboprophylaxis in Orthopedic Surgery | | 2016 |
| Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study | British Journal of Clinical Pharmacology | 2020 |
| Drug-Drug Interactions with Direct Oral Anticoagulants | Clinical Pharmacokinetics | 2020 |
| A Review of the Medical Challenges of Using Direct Oral Anticoagulants in Real-World Practice | Therapeutic Innovation and Regulatory Science | 2020 |
| Cardiovascular Risk Management and Hepatitis C: Combining Drugs | Clinical Pharmacokinetics | 2019 |
| Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation | Drugs and Aging | 2019 |
| Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK | BMJ Open | 2019 |
| Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants | Journal of Thrombosis and Haemostasis | 2019 |
| Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review | Clinical Pharmacokinetics | 2019 |
| How Does "Regulatory Practice" Create Discrepancies in Drug Label Information Between Asian and Western Countries? Different Label Information for Direct Oral Anticoagulants Approved in the United States, Europe, Korea, and Japan | Therapeutic Innovation and Regulatory Science | 2019 |
| Oral Anticoagulation in Patients With Liver Disease | Journal of the American College of Cardiology | 2018 |
| Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation | Thrombosis Journal | 2018 |
| Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs) | Pharmacological Research | 2018 |
| Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study | BMJ Open | 2018 |
| Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice | British Journal of Clinical Pharmacology | 2018 |
| Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians | Journal of Thrombosis and Haemostasis | 2018 |
| Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy | Journal of Pharmaceutical and Biomedical Analysis | 2018 |
| [Spontaneous intraocular hemorrhage under oral anticoagulation : Apixaban in comparison to phenprocoumon] | Ophthalmologe | 2018 |
| Direct-acting oral anticoagulant drug level monitoring in clinical patient management | Journal of Thrombosis and Thrombolysis | 2018 |
| Initial apixaban dosing in patients with atrial fibrillation | Clinical Cardiology | 2018 |
| Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting | Oncologist | 2018 |
| Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban | Current Medical Research and Opinion | 2018 |
| Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury | Journal of the American College of Cardiology | 2018 |
| Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma | Thrombosis and Haemostasis | 2017 |
| Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective | American Journal of Cardiovascular Drugs | 2017 |
| Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis | British Journal of Clinical Pharmacology | 2017 |
| Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs | European Journal of Clinical Pharmacology | 2017 |
| Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study | Journal of Thrombosis and Haemostasis | 2017 |
| Population Pharmacokinetics, Pharmacodynamics, and Exploratory Exposure-Response Analyses of Apixaban in Subjects Treated for Venous Thromboembolism | CPT: Pharmacometrics and Systems Pharmacology | 2017 |
| Management of dental patients receiving antiplatelet therapy or chronic oral anticoagulation: A review of the latest evidence | European Journal of General Practice | 2017 |
| Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future: Views from a workshop at the European Medicines Agency (EMA) | European Heart Journal - Cardiovascular Pharmacotherapy | 2017 |
| Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation | Expert Opinion on Pharmacotherapy | 2017 |
| Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme | International Journal of Laboratory Hematology | 2017 |
| Medication errors involving anticoagulants: Data from the Danish patient safety database | Pharmacology Research and Perspectives | 2017 |
| Perioperative management of patients on direct oral anticoagulants | Thrombosis Journal | 2017 |
| Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation | Journal of Thrombosis and Thrombolysis | 2017 |
| The renal elimination of apixaban: the totality of data relating to the renal clearance of apixaban in patients with impaired renal function: response to Hellfritzsch et al | Pharmacoepidemiology and Drug Safety | 2017 |
| Reply: Apixaban Dosing in Chronic Kidney Disease: Differences Between U.S. and E.U. Labeling | Journal of the American College of Cardiology | 2017 |
| Apixaban Dosing in Chronic Kidney Disease: Differences Between U.S. and E.U. Labeling | Journal of the American College of Cardiology | 2017 |
| Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants | Critical Care | 2017 |
| Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives | Drug Safety | 2016 |
| Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa | American Journal of Cardiovascular Drugs | 2016 |
| Guidance for the prevention and treatment of cancer-associated venous thromboembolism | Journal of Thrombosis and Thrombolysis | 2016 |
| Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants | Cardiovascular Drugs and Therapy | 2016 |
| Drug Treatment of Venous Thromboembolism in the Elderly | Drugs and Aging | 2016 |
| Managing novel orally administered anticoagulants in patients undergoing urogynaecological surgery | International Urogynecology Journal | 2016 |
| Antikoagulation und perioperatives “bridging“ | Coloproctology | 2016 |
| Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE | Thrombosis and Haemostasis | 2016 |
